Fabric Genomics, Salt Lake City, has expanded its somatic cancer system, which provides genomic analysis and clinical reporting to clinical labs. The offering enables therapy-matching for cancer patients, giving clinicians targeted treatment choices for cancer patients. Clinical labs will have access to a single integrated platform for the interpretation of somatic cancer panels, hereditary panels, and whole genomes.
“The Fabric Genomics somatic cancer solution is a natural extension of our already established platform for hereditary diseases, and furthers Fabric Genomics’ goal to improve cancer clinical care through genomic medicine,” says Paul R. Billings, MD, PhD, chief medical officer at Fabric Genomics. “Being able to quickly interpret somatic cancer variants from a tumor or liquid biopsy, and then match those to targeted therapies, is of critical importance to successfully treating cancer patients. Next-generation sequencing (NGS)-based cancer panels are increasingly being used by clinicians to match cancer patients with FDA-approved drugs and experimental therapies, and improve patient outcomes.”
Fabric Genomics’ cancer systems provide an NGS workflow for both inherited cancer risk and somatic cancer testing, including hematology, liquid biopsy, and solid-tumor samples. The company’s expanded somatic cancer capabilities now include variant calling, annotation from cancer-specific databases, clinical curation from multiple providers, and the ability to quickly create physician-ready clinical reports. Somatic variants can be scored and reported in accordance with the 2017 guidelines of the Association for Molecular Pathology, which were created to provide a standardized format for presenting somatic variants in a clinical report.
For more information, visit Fabric Genomics.